No ASX ETF holds Starpharma (SPL) as of 15 Oct 2026. Over the last 3 months it rose 2.7%: on $10,000, +$274. We explain 6 big moves in that time.
About SPL
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$398.2m
- Held by0 ETFs
- Big moves6 in 3M
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- −8.6%peak −10.3%1 Oct 2026· Management
A board chair and deputy chair appointment announcement appears to have unsettled investors, driving an outsized sell-off beyond what sector weakness alone can explain.
- +4.3%peak +5.8%13 Aug 2026· Stake Change
Multiple directors purchased shares through the recently completed $32 million entitlement offer, signalling strong insider confidence and prompting a positive market re-rating of the stock.
- −5.4%12 Aug 2026· Capital Raise
Starpharma launched a $32 million capital raise, causing dilution and a sharp drop in the stock price.
- −7.5%peak −19.9%11 Aug 2026· Capital Raise
Starpharma's stock fell sharply after completing a $32 million renounceable entitlement offer, with new shares being quoted, causing dilution-driven selling pressure.
- +6.7%peak +8.0%5 Aug 2026· Unknown
SPL.AX rose sharply alongside a broader lift in the ASX healthcare sector, likely driven by a general sector rotation or positive sentiment across health stocks rather than any company-specific news.
- +8.0%28 Jul 2026· Sector Flow
SPL.AX rose strongly alongside a broad rally in Australian healthcare sector stocks, lifting the stock on sector-wide buying momentum.
Held by 0 ETFs
No ETF we track holds SPL directly.
Other Health Care companies
- SHLSonic Healthcare47 ETFs
- RMDResMed44 ETFs
- CSLCSL Limited42 ETFs
- BDXBcal36 ETFs
- CSXCleanspace36 ETFs
- REGRegis Health33 ETFs
- TLXTelix Pharma32 ETFs
- SIGSigma Healthcare31 ETFs
Why did SPL fall 7.5% on 11 Aug 2026?
Starpharma
Starpharma's stock fell sharply after completing a $32 million renounceable entitlement offer, with new shares being quoted, causing dilution-driven selling pressure.
Two ASX announcements released just before detection directly confirm the completion of a $32 million entitlement offer and the simultaneous lodging of an Appendix 2A to quote the new securities — both classic triggers for a dilution-driven price drop. The elevated volume (3.3x normal) is consistent with selling by shareholders receiving new shares or those adjusting for dilution. Sector context is counter-evidence (healthcare sector was up 2.15% same day), which rules out sector-wide pressure and strengthens the case that the move is stock-specific and driven entirely by the capital raise announcement.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
Company announcements
News coverage
Sector / macro signals